Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Subjective Evaluation of a Commercially Marketed Contact Lens Amongst a Subset of the Contact Lens Wearing Population: Complete Statistical AnalysisIndependent statistical analysis of Subjective Evaluation of a Commercially Marketed Contact Lens Amongst a Subset of the Contact Lens Wearing Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Subjective Wearing Experience of the Total30 for Astigmatism Lens Among Satisfied Biofinity Toric Lens Wearers: Complete Statistical AnalysisIndependent statistical analysis of Subjective Wearing Experience of the Total30 for Astigmatism Lens Among Satisfied Biofinity Toric Lens Wearers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sublingual vs IV Atropine Bioavailability Study: Complete Statistical AnalysisIndependent statistical analysis of Sublingual vs IV Atropine Bioavailability Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04290039).
- SUBQ-HFIndependent statistical analysis of Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03170219).
- SubQStim: A Post-market Study of Subcutaneous Nerve Stimulation in Failed Back Surgery Syndrome (FBSS) Patients: Complete Statistical AnalysisIndependent statistical analysis of SubQStim: A Post-market Study of Subcutaneous Nerve Stimulation in Failed Back Surgery Syndrome (FBSS) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder: Complete Statistical AnalysisIndependent statistical analysis of Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00383786).
- Substance P Challenge in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Substance P Challenge in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04676763).
- Substituting Sitting With Standing and Walking in Free-living Conditions Improves Daily Glucose Profile in South Asians: Complete Statistical AnalysisIndependent statistical analysis of Substituting Sitting With Standing and Walking in Free-living Conditions Improves Daily Glucose Profile in South Asians: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care: Complete Statistical AnalysisIndependent statistical analysis of Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00355368).
- Suction Cervical Stabilizer Compared to Standard Tenaculum for Intrauterine Procedures: Complete Statistical AnalysisIndependent statistical analysis of Suction Cervical Stabilizer Compared to Standard Tenaculum for Intrauterine Procedures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06193590).
- Sugammadex Provide Better Surgical Condition Compared With Neostigmine in Laryngeal Microsurgery.: Complete Statistical AnalysisIndependent statistical analysis of Sugammadex Provide Better Surgical Condition Compared With Neostigmine in Laryngeal Microsurgery.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular: Complete Statistical AnalysisIndependent statistical analysis of Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03322657).
- SUHRIIndependent statistical analysis of The Substance Use and Health Risk Intervention (SUHRI) for Justice-involved Youth: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Sulindac and Breast Density in Women at Risk of Developing Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sulindac and Breast Density in Women at Risk of Developing Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SUMMITIndependent statistical analysis of A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SUMMIT-LTSIndependent statistical analysis of Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- SUN 1120Independent statistical analysis of Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- SUN1058Independent statistical analysis of A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone: primary endpoint results, effect estimate with confidence interval,…
- Sunitinib and Capecitabine for First Line Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib and Capecitabine for First Line Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00961571).
- Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Sunitinib in Never-Smokers With Lung Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib in Never-Smokers With Lung Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01829217).
- Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC): Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC): Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Sunitinib Non Small Cell Lung Cancer Patients Over 70: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib Non Small Cell Lung Cancer Patients Over 70: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00864721).
- Sunitinib to Treat Recurrent Brain Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sunitinib to Treat Recurrent Brain Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00923117).
- SUNLIGHTIndependent statistical analysis of Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- SUNRISEIndependent statistical analysis of Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Sunshine 2 Study for Women With Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Sunshine 2 Study for Women With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01904032).
- superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology: Complete Statistical AnalysisIndependent statistical analysis of superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03585959).
- Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux: Complete Statistical AnalysisIndependent statistical analysis of Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01499953).
- SuperShelfIndependent statistical analysis of A Multilevel Intervention in the Hunger Relief Network to Improve Diet Among Adults Experiencing Food Insecurity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SUPPORTIndependent statistical analysis of A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Supported Employment in Patient Aligned Care Teams: Complete Statistical AnalysisIndependent statistical analysis of Supported Employment in Patient Aligned Care Teams: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02400736).
- Supporting Oral Pre-exposure Prophylaxis Decision Making Among Pregnant Women in Lilongwe, Malawi: Complete Statistical AnalysisIndependent statistical analysis of Supporting Oral Pre-exposure Prophylaxis Decision Making Among Pregnant Women in Lilongwe, Malawi: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SUPPRESSIndependent statistical analysis of Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery: Complete Statistical AnalysisIndependent statistical analysis of Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01352416).
- SURE-PDIndependent statistical analysis of Safety of Urate Elevation in Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00833690).
- Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.: Complete Statistical AnalysisIndependent statistical analysis of SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…